https://biotechmorning.com/news/ai-designed-drug-crosses-human-brain Biotech Morning en 2026-06-23T14:27:02.041Z The AI-Designed Drug That Just Crossed Into the Human Brain https://biotechmorning.com/news/cancer-treatment-on-body-injector-uk-approval Biotech Morning en 2026-06-23T14:26:17.473Z Cancer Treatment Just Left the Hospital Building https://biotechmorning.com/news/merck-calderasib-keytruda-kras-lung-cancer-breakthrough Biotech Morning en 2026-06-23T14:25:29.254Z Merck Found a Way to Make Keytruda Even Better at Killing Lung Cancer https://biotechmorning.com/news/pfizer-seagen-adc-lung-cancer-phase-3-failure Biotech Morning en 2026-06-23T14:24:42.126Z Pfizer Spent $43 Billion on Seagen. Its First Big Test Just Flopped. https://biotechmorning.com/news/first-disease-modifying-therapy-childhood-type-1-diabetes Biotech Morning en 2026-06-23T14:23:59.095Z The Drug That Tells Type 1 Diabetes to Wait https://biotechmorning.com/news/cemdisiran-quarterly-shot-myasthenia-gravis-fda-priority-review Biotech Morning en 2026-06-23T14:23:12.561Z The Shot You Take Once a Quarter That Could Reshape Myasthenia Gravis https://biotechmorning.com/news/exelixis-zanzalintinib-colorectal-cancer-endpoint-miss Biotech Morning en 2026-06-23T14:22:22.014Z Exelixis Built a Backup Plan for Its $2B Drug. It Just Hit a Wall. https://biotechmorning.com/news/fda-operation-trailblazer-phase-1-acceleration Biotech Morning en 2026-06-23T14:21:35.367Z The FDA Just Found 12 Months Hiding in Its Own Paperwork https://biotechmorning.com/news/merck-tulisokibart-phase-3-ulcerative-colitis-results Biotech Morning en 2026-06-23T14:20:48.553Z Merck's $10.8 Billion Bet on Gut Health Just Passed Its Biggest Test https://biotechmorning.com/news/fda-real-time-clinical-trials-astrazeneca-amgen-2 Biotech Morning en 2026-06-23T14:19:59.365Z The FDA Wants to Watch Your Clinical Trial Live. Like, Right Now. https://biotechmorning.com/news/fda-moderna-white-house-pressure-reversal Biotech Morning en 2026-06-22T14:28:21.196Z The FDA Said No to Moderna. Then the President Called. https://biotechmorning.com/news/lsd-pill-crushes-depression-drugs-phase-3 Biotech Morning en 2026-06-22T14:27:29.516Z An LSD Pill Just Crushed Every Depression Drug in a Phase 3 Trial https://biotechmorning.com/news/novo-nordisk-cagrisema-loses-head-to-head-lilly-tirzepatide Biotech Morning en 2026-06-22T14:26:38.200Z Novo Nordisk Built a Lilly-Killer. It Just Lost the Fight. https://biotechmorning.com/news/bionyra-launches-165-million-inflammation-immunology Biotech Morning en 2026-06-22T14:25:45.411Z A French Biotech Just Raised the Biggest Series A in the Country's History. Here's the Playbook. https://biotechmorning.com/news/lilly-alzcure-alzheimer-billion-dollar-deal Biotech Morning en 2026-06-22T14:24:51.975Z Lilly's $10 Million Bet That Could Be Worth 100x More https://biotechmorning.com/news/big-pharma-106-billion-shopping-spree-2026 Biotech Morning en 2026-06-22T14:23:52.258Z Big Pharma Is on a $106 Billion Shopping Spree. Here's What They're Buying. https://biotechmorning.com/news/pfizer-innovent-10-billion-oncology-deal Biotech Morning en 2026-06-22T14:22:49.816Z Pfizer Just Bought 12 Cancer Programs in Five Months Flat https://biotechmorning.com/news/insilico-sk-biopharmaceuticals-ai-neuroimmune-deal Biotech Morning en 2026-06-22T14:21:56.437Z The $2.5 Billion Bet That AI Can Crack the Brain's Immune System https://biotechmorning.com/news/fda-real-time-clinical-trials-initiative-2 Biotech Morning en 2026-06-22T14:20:59.600Z The FDA Just Gave Itself a Live Feed Into Clinical Trials https://biotechmorning.com/news/abbvie-apogee-therapeutics-acquisition-10-billion Biotech Morning en 2026-06-22T14:20:04.273Z AbbVie Just Dropped $10.9 Billion on a Company That Didn't Exist Four Years Ago